UltraSound - Technology Information PortalSaturday, 25 November 2017
Info
  Sheets



Out-
      side
 




 
 'Phospholipid' 
SEARCH FOR   
 
  12345ABCDEFGHIJKLMNOPQRSTUVWZ
Result : Searchterm 'Phospholipid' found in 1 term [] and 7 definitions [])
1 - 5 (of 8)     next
Result Pages : [1]  [2]
US Resources  
UltraSound Technician and Technologist Schools - Universities - Kidney - - Resources - Services and Supplies
 
PhospholipidMRI Resource Directory:<br> - Contrast Agents -
 
Phospholipids are a major component of all biological membranes. When placed in water, phospholipids form a bilayer, where the hydrophobic tails line up against each other. This forms a membrane with hydrophilic heads on both sides. This membrane is partially permeable and very flexible.
Phospholipid containing microbubbles are in use as diagnostic ultrasound contrast agents. Phospholipids can be targeted to atheroma and other pathologic components to enhance atherosclerosis imaging. The majority of these echogenic liposomes range in diameter from 0.25 to 5.0 µm.
spacer
• Related Searches:
    • Induced Acoustic Emission
    • Persistence
    • Ultrasonic Contrast Agents
    • SonoVue®
    • Acoustically Active Lipospheres

Searchterm 'Phospholipid' was also found in the following service: 
spacer
MRI  (1) Open this link in a new window
AI-700InfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
From Acusphere Inc
AI-700 is an US contrast agent, usable for myocardial perfusion undergoing regulatory FDA approval. The synthetic polymers used in AI-700 do not break during the ultrasound imaging procedure. The used perfluorocarbon filling gas is less soluble in water and therefore has the propensity to stay inside the contrast agent particles. As a result, a higher concentration of gas is delivered to the myocardium over a longer period of time, thereby enabling AI-700 to target the broader application of myocardial perfusion assessment.
AI-700 is a dry powder consisting of small, porous microparticles filled with perfluoropropane. These microparticles are made of a synthetic biodegradable polymer, called poly (D, L-lactide co-glycolide), or PLGA, that has been used in other drug delivery systems approved by the FDA.
The composition and structure of the phospholipid containing microparticles and the properties of the perfluorocarbon gas slow the rate at which the gas dissolves and prevent the microparticles from being quickly broken down. The powder is to suspend in sterile water and injected by a single intravenous injection prior to ultrasound imaging.

In June 2004, Acusphere entered into a Collaboration, License and Supply Agreement with Nycomed Danmark APS for the European development and marketing rights to Acusphere’s lead product candidate AI-700.
Nycomed will be responsible for sales, marketing and the regulatory submissions required for marketing throughout its sales territory, which includes the member states of the European Union, as well as Russia/CIS and the Baltic States.

Drug Information and Specification:
RESEARCH NAME AI 700
DEVELOPER Acusphere, Inc.
INDICATION -
DEVELOPMENT STAGE
myocardial perfusion
APPLICATION Intravenous injection
TYPE Microbubble
SHELL Poly-L-lactide co glycolide
CHARGE Negative
GAS Perfluorocarbon
MICROBUBBLE SIZE -
PREPARATION Reconstitute with water
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer

• View the news results for 'AI-700' (3).



 Further Reading:
  News & More:
Acusphere's AI-700 Pilot Study Exceeds ExpectationsOpen this link in a new window
Thursday, 6 January 2005   by www.thefreelibrary.com    
Acusphere Reaches AI-700 Clinical Trial Milestone; 300 Patients Enrolled in Phase 3 Clinical ProgramOpen this link in a new window
Thursday, 16 December 2004   by phx.corporate-ir.net    
A Method for Radiation-Force Localized DrugDelivery Using Gas-Filled Lipospheres(.pdf)Open this link in a new window
Wednesday, 7 July 2004   by www.ncbi.nlm.nih.gov    
Acusphere Completes Enrollment in Second Phase 3 ClinicalOpen this link in a new window
Friday, 5 May 2006   by phx.corporate-ir.net    
US Resources  
Vascular - Probes Transducers - UltraSound Training Courses - Resources - Rental - General
 
BR14InfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
From Bracco Research SA, Geneva, Switzerland,
BR14 is a new experimental ultrasound contrast agent, consisting of bubbles containing a high molecular weight filling gas enclosed by a flexible phospholipid monolayer shell a few nanometers thick.
This agent shows significant non-linear scattering and agent modification even at low insonation pressures, the detection pulses used did not destroy the contrast bubbles. The results obtained with HPD before the release burst show that the BR14 bubbles are efficient scatterers that can be modified and, thus, detected by low power insonation.

Drug Information and Specification:
RESEARCH NAME BR14
DEVELOPER Bracco Diagnostics, Inc.
DEVELOPMENT STAGE Preclinical
APPLICATION -
TYPE Microbubble
SHELL -
CHARGE Negative
GAS Perfluorobutane
MICROBUBBLE SIZE Mean size 3µm, 95% < 10µm
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer

 Further Reading:
  News & More:
The role of ultrasound in molecular imaging(.pdf)Open this link in a new window
2003   by bjr.birjournals.org    
US Resources  
Universities - DICOM - General - Prenatal - Developers - Portable UltraSound
 
BY 963InfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
By Byk-Gulden (now Altana);
The transpulmonary echo contrast agent under development, BY 963, promises to be an excellent ultrasound contrast agent for the noninvasive assessment of left ventricular function. Intravenous administration of BY 963 phospholipid microbubbles improves the reproducibility of e.g. quantitative analysis.
spacer

Searchterm 'Phospholipid' was also found in the following service: 
spacer
MRI  (1) Open this link in a new window
Coherent Contrast ImagingInfoSheet: - Modes - 
Intro, 
Overview, 
Types of, 
etc.MRI Resource Directory:<br> - Modes -
 
(CCI) A major limitation of the use of ultrasound contrast agents is the problem that signals from the microbubbles are mixed with those from tissue, so that the distribution of the microbubbles is not optimally displayed either in Doppler or gray scale.
Coherent contrast imaging is a high frame rate implementation of inverting the phase of alternate sound pulses and summing the resulting echoes. The symmetrical signals from linear reflectors are cancelled leaving those from non-linear scatterers, with the advantage that the cancellation is performed without the need to transmit two pulses per image line so that bubble destruction is minimized. Coherent contrast imaging yields best results in the vascular phase of phospholipid microbubbles (such as Definity and SonoVue).
See also Coherence.
spacer

US Resources  
Artifacts - Pediatric - PACS - Cardiac - Pelvic - UltraSound Training Courses
 
Related Searches:
 • Persistence
 • Acoustically Active Lipospheres
 • Induced Acoustic Emission
 • Negative Bolus
 • SonoRx
SEARCH FOR   
 
  12345ABCDEFGHIJKLMNOPQRSTUVWZ
     1 - 5 (of 8)     next
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

US-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  


Look
      Ups



UltraSound - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2006 - 2016 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertising
 [last update: 2015-03-04 09:17:02]